ERBB2 gene shows gain-of-function in some cancer types, such as bladder carcinoma (BLCA), breast carcinoma (BRCA), cervical squamous cell carcinoma (CESC), cholangiocarcinoma (CHOL), esophageal carcinoma (ESCA), glioblastoma (GBM), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), thyroid cancer (THCA), and uterine corpus endometrial carcinoma (UCEC). This evidence concerns the gene ERBB2 and cutaneous melanoma.